Proteomics

Dataset Information

0

EAE Optic Nerve Injections with LPC 18:1 (iTRAQ)


ABSTRACT: EAE mice were injected with LPC 18:1 at the optic nerve when they exhibited a clinical score of 2. Visual function was assessed via pattern electroretinogram and optic nerves were harvested 12 days post optic nerve injection. Three different visual recovery pathways were observed: 1) No-injection control (no recovery in visual function), 2) Low recovery visual function, 3) High recovery visual function and 4) No change in visual function.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Optic Nerve

DISEASE(S): Multiple Sclerosis

SUBMITTER: Sanjoy Bhattacharya  

LAB HEAD: Sanjoy Bhattacharya

PROVIDER: PXD024966 | Pride | 2022-02-17

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
ITRAQ.mzML Mzml
ITRAQ.mzid.gz Mzid
ITRAQ.raw Raw
ITRAQ_R2.mzML Mzml
ITRAQ_R2.mzid.gz Mzid
Items per page:
1 - 5 of 7
altmetric image

Publications

Lyso-Lipid-Induced Oligodendrocyte Maturation Underlies Restoration of Optic Nerve Function.

Valdivia Anddre Osmar AO   Bhattacharya Sanjoy K SK  

eNeuro 20220126 1


Protein hyperdeimination and deficiency of lyso-phospholipids (LPC 18:1) has been associated with the pathology of demyelinating disease in both humans and mice. We uncovered interesting biology of LPC 18:1, in which LPC 18:1 induced optic nerve function restoration through oligodendrocyte maturation and remyelination in mouse model systems. Our <i>in vitro</i> studies show LPC 18:1 protection against neuron-ectopic hyperdeimination and stimulation of oligodendrocyte maturation, while <i>in vivo  ...[more]

Similar Datasets

2022-02-17 | PXD025176 | Pride
2016-08-24 | PXD001581 | Pride
2020-11-24 | PXD022661 | Pride
2009-07-01 | GSE11935 | GEO
2018-01-13 | MSV000081934 | MassIVE
2013-07-15 | E-GEOD-40857 | biostudies-arrayexpress
2024-04-10 | GSE251716 | GEO
2024-04-10 | GSE250615 | GEO
2018-10-03 | ST001073 | MetabolomicsWorkbench
2024-07-03 | GSE244627 | GEO